Back to Search
Start Over
Randomized, Assessor-Blinded Trial Comparing Highly Purified Human Menotropin and Recombinant Follicle-Stimulating Hormone in High Responders Undergoing Intracytoplasmic Sperm Injection
- Source :
- Obstetrical & Gynecological Survey. 76:34-35
- Publication Year :
- 2021
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2021.
-
Abstract
- Objective To evaluate the efficacy and safety of highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (rFSH) for controlled ovarian stimulation in a population of patients predicted to be high responders. Design Randomized, open-label, assessor-blinded, parallel-group, noninferiority trial. Setting Fertility centers. Patient(s) A total of 620 women with serum antimullerian hormone (AMH) ≥5 ng/mL. Intervention(s) Controlled ovarian stimulation with HP-hMG or rFSH in a GnRH antagonist assisted reproductive technology (ART) cycle. Fresh transfer of a single blastocyst was performed unless ovarian response was excessive, in which all embryos were cryopreserved. Subjects could undergo subsequent frozen blastocyst transfer within 6 months of randomization. Main Outcome Measure(s) Ongoing pregnancy rate (OPR) after fresh transfer (primary endpoint), as well as cumulative live birth, ovarian hyperstimulation syndrome (OHSS), and pregnancy loss rates. Results OPR/cycle start after fresh transfer was 35.5% with HP-hMG and 30.7% with rFSH (difference: 4.7%, 95% CI −2.7%, 12.1%); noninferiority was established. Compared to rFSH, HP-hMG was associated with significantly lower OHSS (21.4% vs. 9.7% respectively; difference: −11.7%, 95% CI −17.3%, −6.1%) and cumulative early pregnancy loss rates (25.5% vs. 14.5% respectively; difference: −11.0%, 95% CI −18.8%, −3.14%). Despite 43 more transfers in the rFSH group, cumulative live birth rates were similar with HP-hMG and rFSH at 50.6% and 51.5% respectively (difference: −0.8%, 95% CI −8.7%, 7.1%). Conclusion(s) In high responders, HP-hMG provided comparable efficacy to rFSH with fewer adverse events, including pregnancy loss, suggesting its optimized risk/benefit profile in this population. Clinical Trial Registration Number NCT02554279 ( clinicaltrials.gov ).
- Subjects :
- 0301 basic medicine
Anti-Mullerian Hormone
Male
Pregnancy Rate
medicine.medical_treatment
Ovarian hyperstimulation syndrome
Intracytoplasmic sperm injection
0302 clinical medicine
Pregnancy
Single Embryo Transfer
Prospective Studies
education.field_of_study
030219 obstetrics & reproductive medicine
Obstetrics and Gynecology
General Medicine
Recombinant Proteins
Treatment Outcome
Female
Follicle Stimulating Hormone, Human
Live birth
Live Birth
Adult
Ovulation
medicine.medical_specialty
Menotropins
High responder
Early Pregnancy Loss
Recombinant Follicle Stimulating Hormone
Population
Andrology
03 medical and health sciences
Ovarian Hyperstimulation Syndrome
Young Adult
Ovulation Induction
medicine
Humans
Sperm Injections, Intracytoplasmic
education
Gynecology
Assisted reproductive technology
business.industry
Ovary
Fertility Agents, Female
medicine.disease
United States
Abortion, Spontaneous
030104 developmental biology
Fertility
Reproductive Medicine
Infertility
Menotropin
business
Biomarkers
Subjects
Details
- ISSN :
- 15339866 and 00297828
- Volume :
- 76
- Database :
- OpenAIRE
- Journal :
- Obstetrical & Gynecological Survey
- Accession number :
- edsair.doi.dedup.....365854aecbb8849565acd2e09dfb0ca9